Biocon Biologics Adds Keytruda, Herceptin, Opdivo Biosimilars To Its Portfolio
Biocon Biologics continues to build on its oncology portfolio with three new biosimilar candidates, as the integration into a wholly owned subsidiary of Biocon Limited comes closer.
Generics Bulletin - January 9, 2026

Hyloris Taps Rosemont To Commercialize Titratable Atomoxetine Oral Solution In US
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Generics Bulletin - January 9, 2026

Cosette And Alembic Are Among Latest To Benefit From CGT Pathway
Cosette Pharmaceuticals and Alembic Pharmaceuticals are among the latest firms to have benefited from 180 days of competitive generic therapy exclusivity under the US FDA’s CGT pathway. Since the first approval in 2018, almost 500 ANDAs referencing CGT products have been approved.
Generics Bulletin - January 9, 2026

BSI’s Tunbridge: Notified Bodies ‘Set Up To Fail’ Unless EU Legislative Proposal Changes
Proposal Gives Unrealistic Timelines And Reflects Poor Grasp Of Notified Body Realities
Medtech Insight - January 9, 2026

How Do Aurobindo’s Khandelwal Acquisition, Amicus Settlement, China JV Move Add Up?
What is the strategic intent behind Aurobindo’s moves to settle a Galafold patent dispute with Amicus Therapeutics, acquire the non-oncology business of compatriot Khandelwal Labs and get full control of a Chinese JV with Shandong Luoxin?
Scrip - January 9, 2026

Roche Doubles Down On SCLC By In-Licensing MediLink’s ADC
Deal Snapshot: Roche has scooped up a B7H3 ADC from China’s MediLink just a few months after Daiichi Sankyo temporarily halted enrolling patients in a pivotal Phase III trial with its same-class rival, Merck-partnered ifinatamab deruxtecan (I-DXd).
Scrip - January 9, 2026

Hisamitsu To Go Private For Long-Term Growth Through $2.6bn MBO
Hisamitsu's CEO is taking the Japanese firm private through a management buyout aimed at securing future growth.
Scrip - January 9, 2026

CES Beauty Tech Honorees Offer Window Into Future Skin, Hair Innovations
The Consumer Technology Association’s CES show in Las Vegas Jan. 6-9 showcased breakthrough skin and hair care technologies.
HBW Insight - January 9, 2026

Inno Medicine Moves Novel Liposome Into Pivotal Trial For Coronary Plaque
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
Scrip - January 9, 2026